SOF-SKN™ manufacturing begins to ensure clinical trial readiness

Highlights

- **Key ingredients now being made**
- **Process expected to take several weeks**
- **Low supply chain risks**

Sydney, 9 June 2026: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce it has commenced SOF-SKN™ manufacturing for a clinical trial being planned for later this year.

The manufacturing process is expected to take several weeks, including quality control checks involving a battery of physical, chemical and biological tests.

Taking place in a controlled environment, manufacturing utilises a proven methodology that supports future efficiencies and low supply chain risks. This efficiency is further reinforced by a favourable active ingredient stability profile, enabling the adoption of a strategic drug manufacture approach.

Noxopharm will also use the manufactured product as part of preclinical investigations around dose range-finding experiments and therapeutic models, as well as further characterisation of SOF-SKN and its overall stability profile, which has been shown to be very good.

Noxopharm CEO Dr Olivier Laczka said: "Following the success of our Phase I HERACLES trial and the lack of targeted treatments on the market for people with cutaneous lupus erythematosus (CLE), we are preparing to be ready for any opportunity to test SOF-SKN in patients.

"Currently, we are actively investigating prospects for a pilot study in a local patient population, which would act as a valuable guide for a future Phase II trial. We will update shareholders in due course and are looking to progress this project as quickly as possible."

SOF-SKN is initially being developed for the chronic inflammation caused by the autoimmune disease cutaneous lupus erythematosus (CLE), before potential expansion into additional autoimmune-related skin diseases, such as psoriasis and dermatomyositis.

The global CLE market is worth more than US$3.3 billion and is expected to grow significantly over the coming years. Beyond dermatology, the underlying Sofra™ technology may also support future development opportunities across a broader range of diseases associated with immune system dysregulation, including rheumatoid arthritis and diabetes.

-ENDS-

NOXOPHARM

About the Sofra technology platform

Developed from a breakthrough discovery in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as enhancing RNA therapeutics and vaccines.

Sofra technology has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: SOF-SKN / SOF-VAC

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
Shawn van Boheemen
T: +61 414 903 376
E: shawn.vanboheemen@noxopharm.com

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.